GLP-1 'weird side effects': what the science actually says

What's this video probably claiming?

Based on the caption, @glp1.ash is describing sensory and food aversion side effects that caught her off guard during GLP-1 therapy. Specifically, she mentions a temporary intolerance to boiled eggs lasting roughly two months, and a perceptual change where sparkling water started tasting spicy or metallic. The video appears to be framed as a relatable community share, not medical advice, which is a meaningful distinction. But with 7.5K views and hashtags like #glp1girlies and #glp1community, these anecdotal experiences travel fast and often get interpreted as universal or predictable drug effects. The implicit claim is that GLP-1 receptor agonists cause unusual sensory changes and specific food aversions beyond the commonly cited nausea and vomiting. That framing deserves scrutiny, because some of it holds up, and some of it is harder to pin to the drug itself.

What does the science actually show?

GLP-1 receptors are expressed in the gut, brainstem, and areas of the brain involved in reward and sensory processing, including the nucleus tractus solitarius. This means GLP-1 agonists like semaglutide and tirzepatide are not purely mechanical appetite suppressors. They genuinely alter food reward signaling. A 2022 study by Blundell et al. in Diabetes, Obesity and Metabolism found that semaglutide 2.4mg reduced hedonic hunger and food cue reactivity, not just caloric intake. Food aversions, including to high-protein foods like eggs, are plausible given sulfur compounds and gastroparesis-adjacent slowing. Gastric emptying delay, documented in trials including the STEP 1 trial (Wilding et al., 2021, NEJM), can make previously tolerable foods suddenly nauseating. The carbonated water complaint is less studied but likely relates to altered chemosensory thresholds or heightened CO2 sensitivity, possibly mediated by central GLP-1 receptor activity. This is speculative territory, but not implausible.

Where does the social media noise diverge from clinical reality?

Here is where it gets messy. The #glp1community ecosystem tends to present individual anecdotes as near-universal drug effects, and that conflation is a problem. Food aversions to eggs are not listed in prescribing information for semaglutide or tirzepatide. They are plausibly drug-related, but they could also reflect gastroparesis, coincidental aversions from nausea conditioning, or pre-existing sensitivities unmasked by caloric restriction. The clinical trials, including SURMOUNT-1 (Jastreboff et al., 2022, NEJM) for tirzepatide, tracked nausea, vomiting, and diarrhea systematically, but did not granularly document specific food aversions or carbonation sensitivity. Relying on TikTok to build a symptom map for these drugs is a genuinely poor substitute for post-marketing surveillance data. The creator is not doing anything wrong by sharing her experience. The risk is the downstream audience assuming these are predictable, harmless, and self-resolving effects for everyone, when individual variation is enormous.

What should you actually know?

GLP-1 agonists do cause real, documented sensory and gastrointestinal changes beyond the headline nausea statistic. In STEP 1, nausea occurred in roughly 44% of participants on semaglutide 2.4mg versus 16% on placebo, and most adverse GI events peaked in the first 20 weeks and declined. Specific food aversions are biologically plausible but not systematically catalogued, meaning your provider may not have good population-level data to reassure you with. The two-month egg aversion described here falls within a timeframe consistent with gastroparesis-driven food sensitivity, which can resolve as the body adapts. Carbonation tasting spicy is an unusual complaint but not impossible given altered CO2 chemoreception. If you are on a GLP-1 and experiencing unexpected sensory changes, that conversation belongs with a prescribing clinician, not a comment section. Protein deficiency from food aversions during GLP-1 therapy is a documented concern, with some clinicians recommending 1.2 to 1.6g per kg body weight daily to preserve lean mass during rapid weight loss.